Explore this article's sources with AI
Follow PeptideMethods on Google
Is TB-500 safe during pregnancy?
TB-500 has not been shown safe in pregnancy. The only registered study excludes pregnancy, has no results, and there is no regulator-reviewed TB-500 label.
Why we wrote this. People asking about TB-500 in pregnancy need the false-label premise corrected and a direct explanation of why trial exclusion and missing warnings do not establish safety.
In this article (5 sections)
TB-500 has not been shown to be safe during pregnancy. No human pregnancy study has established its effects on the pregnant patient, embryo, fetus, birth outcomes, or child development. The only registered interventional study that names TB-500 is recruiting adults with stable cardiovascular disease, excludes people who are pregnant or breastfeeding, and has no posted results[1]. That distinction matters. An exclusion criterion cannot be read as evidence of safety or evidence that harm occurred.
There is also no regulator-reviewed TB-500 prescribing label. A current search of the FDA approval dataset found no approved application under TB-500, TB 500, thymosin beta-4 fragment 17-23, or LKKTETQ[2]. Seller stickers and research-chemical directions are not substitutes for an approved label. Missing pregnancy wording on those materials offers no reassurance. Our TB-500 overview explains the broader evidence limits.
The registered TB-500 study cannot answer the pregnancy question
ClinicalTrials.gov currently lists NCT07487363, a sponsor-registered Phase 1/2 study of TB-500, identified there as the thymosin beta-4 17-23 fragment. The record describes a planned enrolment of 80 adults aged 40 to 75 with stable atherosclerotic cardiovascular disease. Its aims include safety and tolerability, alongside pharmacokinetics and exploratory cardiovascular biomarkers[1]. This is not a pregnancy study, and it does not test injury-recovery claims often attached to products sold under the same name.
The registry excludes anyone who is pregnant or breastfeeding, as well as participants of childbearing potential who are unwilling to use effective contraception during the study[1]. That boundary protects the study population; it does not reveal what TB-500 does during pregnancy. The record was verified as recruiting in November 2026 and gives future estimated completion dates. No results have been posted. Eligibility rules from an unfinished trial cannot supply outcome data that were never collected from the excluded population.
There is no approved TB-500 pregnancy label
The brief behind this question refers to a label, but that premise needs correction. FDA's Drugs@FDA files catalogue approved drug applications and were updated on 13 November 2026. Exact identity searches performed for this article found no approved TB-500 product or active ingredient under the four names above[2]. The bounded finding is that no FDA-approved TB-500 application was identified; it is not a claim that every product or legal category worldwide was searched.
FDA explains that an unapproved drug has not been reviewed for safety, effectiveness, or quality. The agency also warns that, without its review, there is no assurance that a product's label is complete and accurate or that manufacturing produces consistent quality[3]. This general FDA statement does not provide TB-500 pregnancy outcomes. It explains why silence on an online label cannot be treated like a regulator's pregnancy risk assessment.
The wider human evidence is too limited for reassurance
A 2026 review of approved and unapproved peptides identifies TB-500 as a thymosin beta-4 fragment and says rigorous human safety data for unapproved peptides are scarce[4]. That review is not a pregnancy study and cannot quantify a pregnancy risk. It does, however, reinforce the central evidence boundary: animal tissue-repair findings and general peptide mechanisms are not human reproductive-safety evidence.
The molecule named in a paper or registry may also differ from a product sold online. A seller's product may have uncertain identity and concentration; its purity, formulation, and storage history may also be unknown. Research on full-length thymosin beta-4 should not automatically be transferred to the shorter fragment described as TB-500, and neither evidence stream validates an unverified vial. Those product uncertainties sit on top of the missing pregnancy data. They do not fill it.
If exposure has already occurred
An exposure does not prove that harm occurred, but current evidence cannot provide online reassurance either. CDC advises people who are pregnant or planning pregnancy to talk with a healthcare professional before starting or stopping medicines. It also notes that pregnancy safety information is often limited because pregnant people are commonly excluded from studies[5]. That general guidance does not amount to TB-500-specific clearance.
A clinician assessing a past exposure may need the product name, route, dates, packaging, and any available lot or ingredient details. Sharing those facts helps define what is known and unknown, but it cannot authenticate an unregulated product. Decisions about an actual pregnancy, the condition being treated, or changes to care require an individualized clinical assessment rather than a generic internet answer.
What we do not yet know
Direct human evidence has not established miscarriage risk, congenital-malformation risk, placental transfer, effects on fetal growth, preterm birth, delivery outcomes, longer-term child development, or safety during breastfeeding. No dose, route, trimester, or exposure window has been shown safe. The current registry exclusion leaves these questions unanswered, and the absence of an approved label removes a source that would otherwise summarize regulator-reviewed reproductive data.
The evidence-based conclusion is therefore limited but clear: TB-500 cannot be called safe during pregnancy. Trial exclusion is not a hidden safety finding, and a missing warning on seller material is not permission to use it. The TB-500 safety section covers other uncertainties, but it does not provide pregnancy clearance.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Is TB-500 safe during pregnancy?
TB-500 has not been shown to be safe during pregnancy. No direct human pregnancy study has established effects on the pregnant patient or fetus, including outcomes after birth.
Does TB-500 have a pregnancy warning on an approved label?
There is no FDA-approved TB-500 prescribing label. Seller directions and research-chemical stickers are not regulator-reviewed pregnancy risk assessments, so missing warnings do not establish safety.
Were pregnant people included in the registered TB-500 trial?
No. NCT07487363 excludes people who are pregnant or breastfeeding and has no posted results. Exclusion means the study cannot answer the pregnancy question; it is not evidence of safety or observed harm.
What if TB-500 exposure happened before pregnancy was known?
An exposure does not prove harm, but the evidence is too limited for online reassurance. A qualified healthcare professional can assess the product, route, timing, packaging, symptoms, and individual clinical context.
Sources
- [1]ClinicalTrials.gov: NCT07487363 TB-500 cardiovascular biomarker study recordTier 1 · primary↩
- [2]FDA: Drugs@FDA data filesTier 1 · primary↩
- [3]FDA: Unapproved drugsTier 1 · primary↩
- [4]Mendias and Awan (2026): Safety and efficacy of approved and unapproved peptide therapiesTier 2 · expert↩
- [5]CDC: Medicine and pregnancy, an overviewTier 1 · primary↩
No revisions yet. First published .